Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial

Venkatraman Radhakrishnan1,2, Sameer Bakhshi2, Smita Kayal3, Cherian Thampy1, Ankit Batra1, Praveen Kumar Shenoy1, Hemanth Kumar1, Swaminathan Rajaraman4, Shilpi Chaudhary2, Reema Bisht2, Biswajit Dubashi3 and Trivadi S. Ganesan1

© The Author(s) 2022

The benefit of three-drug induction chemotherapy over a two-drug induction has not been evaluated in pediatric acute myeloid leukemia (AML). We, therefore, conducted a randomized controlled trial to ascertain the benefit of a three-drug induction regimen. Patients aged 1–18 years with newly diagnosed AML were randomized to two cycles of induction chemotherapy with daunorubicin and ara-C (DA) or two cycles of ara-C, daunorubicin, and etoposide (ADE). After induction, patients in both arms received consolidation with two cycles of high-dose ara-C. The study’s primary objective was to compare the event-free survival (EFS) between the two arms. The secondary objectives included comparing the composite complete remission (cCR) rates, overall survival (OS), and toxicities. The study randomized 149 patients, 77 in the DA and 72 in the ADE arm. The median age was 8.7 years, and 92 (62%) patients were males. The median follow-up was 50.9 months. The cCR rate in the DA and ADE arm were 82% and 79% (p = 0.68) after the second induction. There were 13 (17%) induction deaths in the DA arm and 12 (17%) in the ADE arm (p = 0.97). The 5-year EFS in the DA and ADE arm was 34.4% and 34.5%, respectively (p = 0.74). There were no significant differences in toxicities between the regimens. There was no statistically significant difference in EFS, OS, CR, or toxicity between ADE and DA regimens in pediatric AML. The trial was registered with the Clinical Trial Registry of India (Reference number: CTRI/2014/11/005202).

Blood Cancer Journal (2022) 12:131; https://doi.org/10.1038/s41408-022-00726-1

INTRODUCTION

Acute myeloid leukemia (AML) is rare in children compared to older adults [1]. Over the last few decades, there has been a significant improvement in survival in pediatric AML in high-income countries (HICs) [2]. This improvement has been achieved through better risk stratification, improved supportive care, and allogeneic hematopoietic stem cell transplantation (HSCT) [3, 4]. The outcomes of pediatric AML in low-income countries (LICs) and low and middle-income countries (LMICs) have been poorer compared to HICs due to limited resources, high cost of treatment, infections, lack of access to allogeneic HSCT, delayed and moribund presentation, and treatment abandonment [5–9].

Unlike other solid and other hematological malignancies where immunotherapy and targeted therapy have changed the treatment landscape, chemotherapy remains the backbone for treating AML. Daunorubicin and ara-C (DA), also called “3 + 7” because of the 3-day daunorubicin and seven-day continuous ara-C infusion schedule, is the standard induction chemotherapy regimen for AML in adults [10]. Pediatric AML induction regimens have been heterogeneous. Most use ara-C, an anthracycline (daunorubicin, idarubicin, or mitoxantrone), and a third drug (etooside, 6TG, or clofarabine). Randomized controlled trials (RCTs) in pediatric AML have not shown the superiority of a specific anthracycline or a specific third chemotherapy drug for induction [11–13].

Adding etoposide to the standard DA induction chemotherapy has not improved outcomes in patients with AML above 15 years [10]. There is no RCT in pediatric AML to show the superiority of a three-drug induction compared to the standard 2-drug induction. We, therefore, conducted an RCT comparing the two-drug DA regimen with the three-drug ADE regimen (DA with etoposide) in pediatric AML since ADE is the most common induction regimen used in children with AML.

METHODS

Study design and patients

The study was an investigator-initiated, multi-center RCT conducted by the Indian Pediatric Oncology Group (IPoG) (reference number: InPoG-AML-16-01). The participating sites included: Cancer Institute (WIA), Chennai; All India Institute of Medical Sciences, New Delhi; and Jawaharlal Nehru Institute of Postgraduate Medical Education and Research, Puducherry. The study was approved by the Institute Ethics Committees of the participating sites and registered with the Clinical Trial Registry of India (Reference number: CTRI/2014/11/005202). Patients were recruited after obtaining written informed consent from their parents. Verbal assent was obtained from children aged 7–12 years, and written assent was obtained from children above 12 years to participate in the study.

We hypothesized that the ADE regimen would be superior to the DA regimen in improving survival in pediatric AML. The study’s primary objective was to compare the event-free survival (EFS) between the DA

1Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India. 2Department of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India. 3Department of Medical Oncology, JIPMER, Puducherry, India. 4Department of Biostatistics, Cancer Institute (WIA) Adyar, Chennai, India. 5Email: venkymd@gmail.com

Received: 11 July 2022 Revised: 23 August 2022 Accepted: 24 August 2022
Published online: 06 September 2022
### Table 1. Chemotherapy doses and schedule for the study regimens.

| Study Arm                          | First Induction          | Second Induction         | First Consolidation | Second Consolidation |
|------------------------------------|--------------------------|--------------------------|---------------------|----------------------|
| Daunorubicin and ara-C (DA)        | Daunorubicin: 60 mg/m² daily by IV infusion over 1 hour on days 1, 2, and 3. | Daunorubicin: 60 mg/m² daily by IV infusion over 1 hour on days 1, 2, and 3. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. |
| ara-C, Daunorubicin and Etoposide (ADE) | ara-C: 100 mg/m², continuous infusion days 1 to 7 inclusive. | ara-C: 100 mg/m², continuous infusion days 1 to 7 inclusive. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. |
|                                     | Daunorubicin: 100 mg/m² twice daily (12 hours apart) IV push on days 1 to 10 inclusive. | Daunorubicin: 100 mg/m² twice daily (12 hours apart) IV push on days 1 to 8 inclusive. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. |
|                                     | Etoposide: 100 mg/m² daily by 4-hour IV infusion on days 1–5 inclusive. | Etoposide: 100 mg/m² daily by 4-hour IV infusion on days 1–5 inclusive. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. | ara-C: 3.0 g/m² 12-hourly by 4-hour IV infusion on days 1, 3 and 5. |

IV Intravenous.

The bold italic values are the names of the chemotherapy drugs used.

and ADE arms. The secondary objectives were to compare the composite complete remission (CCR) rates, toxicities, and overall survival (OS) between the two arms.

The major inclusion criteria were newly diagnosed patients with de novo AML between 1–18 years of age. The following patients were excluded from the study: children with acute promyelocytic leukemia (APML), myelodysplastic syndrome or bi-phenotypic leukemia, or Philadelphia chromosome-positive AML; serum creatinine >2 mg/dl; serum bilirubin >3 mg/dl; pregnancy; cardiac dysfunction either clinically or ejection fraction less than 50% on echocardiography; patients with hepatitis B, hepatitis C, and human immunodeficiency virus infections; previous cytotoxic chemotherapy for AML; patients with genetic disorders like down syndrome and; the physician considered that intensive therapy was not an appropriate treatment option.

**Randomization**

All consecutive patients admitted for treatment were screened for eligibility criteria. Those giving consent were randomized 1:1 to one of the pre-specified two arms (Arm A: DA or Arm B: ADE). The department of Biostatistics at the Cancer Institute assisted in the random allocation of the patients. Randomization was performed by generating random number tables through a customized computer program for the study’s proposed total number of cases. A document was then prepared to allocate all the subjects to the two arms in chronological order. The patient and the investigator were not blinded to the allocation as it was an open-label study.

**Procedures**

The diagnosis of AML was confirmed on morphological examination of the bone marrow aspirate and flow cytometry. Bone marrow aspirates were sent for conventional karyotyping and polymerase chain reaction testing for t(8;21), t(15;17), t(16;16) or inversion 16, t(9;22), fms-like tyrosine kinase 3 (FLT3) gene mutation, and nucleophosmin 1 (NPM1) gene mutation.

The chemotherapy doses and schedule are provided in Table 1 [10]. The study schema is shown in Supplemental Fig. S1. Patients in Arm A received two cycles of induction with DA followed by two cycles of consolidation with high dose ara-C (HIDAC). Patients in Arm B received two cycles of induction with ADE followed by two cycles of consolidation with high dose ara-C (HIDAC). The subsequent chemotherapy cycle was initiated if the patient’s neutrophil counts recovered to \(1 \times 10^{10}/L\) and platelets to \(100 \times 10^{9}/L\).

Patients without central nervous system (CNS) disease at diagnosis received “triple” intrathecal chemotherapy with methotrexate, ara-C, and hydrocortisone, one after each of the first two courses of chemotherapy. Patients with CNS involvement received triple intrathecal chemotherapy twice a week until clearance of blasts in the cerebrospinal fluid and for a minimum of six doses, followed by triple intrathecal chemotherapy at the start of each cycle of chemotherapy.

Complete remission (CR) was defined as less than 5% blasts in the bone marrow aspirate; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) ≥ 1 × 10⁹/L; and platelet count ≥ 100 × 10⁹/L [14]. CR with incomplete hematologic recovery (CRI) was defined as CR criteria except for ANC less than 1 × 10⁹/L or platelet count less than 100 × 10⁹/L [14]. CCR was defined as CR + CRI. A bone marrow aspirate was performed to assess the remission status after 21 days and beyond after starting the first induction, provided the patient had a hematological recovery defined as an absolute neutrophil count (ANC) of more than 1.5 × 10⁹/L and platelets of more than 75 × 10⁹/L. If the bone marrow was hypoplastic and assessment of remission status was not possible, a repeat bone marrow aspiration was performed after an additional 7–10 days to assess the remission status. A bone marrow aspirate was performed on day 42 if the patient did not achieve hematological recovery. Patients in whom the bone marrow remission status was not interpretable after two bone marrows proceeded to receive the second induction based on the investigator’s evaluation of the clinical status. The bone marrow was re-assessed 21 days and beyond after starting the second induction if the patient did not achieve CR after the first induction or if the bone marrow was not evaluable after the first induction. The criteria for bone marrow assessment after the first induction was followed for the second. The disease was considered refractory if the patient did not achieve CR after the second induction, and the patient was withdrawn from the trial. The treatment of patients with refractory disease was based on the treating center’s discretion. Minimal residual disease (MRD) assessment was not performed in the study as it was not available for AML at the treating centers until 2019.

Patients with t(8;21), inv 16 or t(16;16), and NPM1 mutation without FLT-3 internal tandem duplication (ITD) were considered favorable-risk. Patients with FLT-3 ITD, complex cytogenetics (more than three abnormalities), t(6;9), t(3;3), –5, del 5q or –7 were classified as adverse risk. Patients who did not meet either low or high-risk criteria were defined as intermediate risk [14]. Karyotyping, PCR, and morphology were not reviewed centrally.

Allogenic HSCT was considered in patients not in CR after the second induction (refractory disease) and in patients with intermediate or adverse risk, irrespective of the remission status. The decision to proceed with the transplant was based on the availability of donors, finances, physician, and parent preferences. Relapse was defined as bone marrow blasts ≥ 5%;
reappearance of blasts in the blood; or development of extramedullary disease. Treatment-related toxicities were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [15]. The World Health Organization (WHO) AnthroPlus software was used to calculate the patient’s nutritional status at baseline [16]. Patients under five years with a weight for age less than −2 standard deviation (SD) and those five years and above with body mass index (BMI) for age less than −2 SD were considered undernourished. Obesity was defined as weight for age more than +2 SD (under five years) or BMI for age more than +2 SD (five years and above).

**Protocol modification**

The study protocol was modified in June 2017 after it was expanded as a multi-centric study. The primary endpoint was changed from CR rate to EFS based on the inputs of the investigators. This increased the sample size from 186 to 188.

**Statistical analysis**

The sample was calculated based on a 20% difference in EFS with 80% power and a 5% chance level. Ninety-four patients were needed to be recruited in each arm to improve EFS in the DA arm from 35% to 55% in a multi-centric study. The primary endpoint was changed from CR rate to EFS based on the inputs of the investigators. An intention-to-treat analysis was performed. Treatment abandonment was defined as the discontinuation of the planned treatment by the study participant. A study participant was considered lost to follow-up if the participant did not visit the hospital for a review after completing the study treatment or could not be contacted telephonically for more than a year since the last visit or contact.

**RESULTS**

Between 1st June 2014 and 14th November 2019, 149 patients were enrolled and randomized. Seventy-seven patients were randomized to the DA and 72 to the ADE arm. The consort diagram is shown (Fig. 1). The median age was 8.7 years (range: 1–18 years), and 92 (62%) patients were males. Thirty-three (43%) patients in the DA arm and twenty-five (35%) in the ADE arm were undernourished at diagnosis. The baseline characteristics of patients were comparable between the two arms (Table 2).

**Response to induction and induction mortality**

After the first induction, the DA and ADE arm’s cCR rate was 65% and 68% (p = 0.68), respectively. It was 82% and 79% (p = 0.68) after the second induction (Table 3). Two patients had a non-evaluable first bone marrow examination after the first induction and five patients had a non-evaluable first bone marrow examination after the second induction. All the above patients had evaluable bone marrow at the second attempt except one patient after the first induction. This patient achieved CR after the second induction. The median time for performing the first bone marrow post-first induction was 23 days in the DA arm and 24.5 days in the ADE arm. The median time for performing the first-bone marrow post-induction second induction was 23 days in the DA arm and 23 days in the ADE arm (Table 3).

There were 13 (17%) induction deaths in the DA arm (8 in the first and 5 in the second induction) and 12 (17%) in the ADE arm (8 in the first and 4 in the second induction) (p = 0.69). Eleven out of 0.05 was used. All statistical analyses were performed on SPSS (IBM, Chicago, version 17).
of 13 (84.6%) induction deaths in the DA arm and nine out of the 12 (75%) in ADE were due to sepsis (Table 3). Nine out of 13 patients (69.2%) who died during induction in the DA arm and 7 out of 12 patients (58.3%) in the ADE arm were undernourished. There was no induction mortality in obese patients. The induction mortality details are provided in Supplemental Table S1.

Supportive Care During Induction

The mean duration of hospitalization during the first induction in the DA and ADE arm was 23.01 and 21.72 days \((p = 0.46)\). The mean duration of hospitalization during the second induction in the DA and ADE arm was 20.3 and 20.4 days \((p = 0.93)\). There were no significant differences between the DA and ADE arms during the two cycles of induction for blood product support, days of antibiotic use, lines of antibiotic use, therapeutic anti-fungal use, and blood culture positivity (Table 3).

Refractory disease

Nine patients had a refractory disease after completing two cycles of induction, four in DA and five in the ADE arm (Supplemental Table S2). The remission status of seven out of 13 patients who died during induction was unknown as post-mortem bone marrow studies could not be performed (Supplemental Table S1). One patient with refractory disease after the first cycle of induction received HIDAC consolidation omitting the second induction due to poor performance status. This patient abandoned the treatment after the first HIDAC. All except one patient with the refractory disease died at the last follow-up, whose survival status could not be ascertained. Only one patient with refractory disease underwent allogeneic HSCT after achieving CR with salvage chemotherapy. This patient died post-HSCT due to sepsis and encephalitis.

Consolidation

Fifty-eight out of 77 (75.3%) patients in the DA arm and 55 out of 72 (76.3%) patients in the ADE arm received the first HIDAC
Table 3. Comparison of outcomes between the DA and ADE arms.

| Outcome                                                                 | DA (n = 77) (%) | ADE (n = 72) (%) | p value |
|------------------------------------------------------------------------|-----------------|-----------------|---------|
| **Composite complete remission after I1 (CR + CRi)**                   |                 |                 |         |
| Yes                      | 50 (65)         | 49 (68)         | 0.68    |
| CR                       | 45 (90)         | 47 (96)         |         |
| CRi                      | 5 (10)          | 2 (4)           |         |
| No                       | 22 (28.5)       | 15 (20.8)       |         |
| I1 bone marrow evaluation not done                                    |                 |                 |         |
| Died                     | 4               | 7               | 0.89    |
| Abandonment              | 1               | 0               |         |
| Not evaluable            | 0               | 1               |         |
| **Composite complete remission after I2 (CR + CRi)**                  | 50 + 13 = 63 (82)| 49 + 8 = 57 (79) | 0.68    |
| Yes (I1 + I2)            | 12 (92)         | 6 (75)          |         |
| CR                       | 12 (92)         | 6 (75)          |         |
| CRi                      | 1 (8)           | 2 (25)          |         |
| No                       | 6               | 6               |         |
| I2 bone marrow evaluation not done                                    |                 |                 |         |
| Died                     | 3               | 1               | 0.76    |
| Abandonment              | 0               | 1               |         |
| Not evaluable            | 0               | 0               |         |
| **Time to I1 bone marrow evaluation (days)**                          |                 |                 |         |
| Median                   | 23              | 24.5            | 0.15    |
| Mean, SD                 | 24.21 (4.24)    | 25.27 (4.37)    |         |
| **Time to I2 bone marrow evaluation (days)**                          |                 |                 |         |
| Median                   | 23              | 23              | 0.87    |
| Mean, SD                 | 23.06 (4.05)    | 23.29 (4.03)    |         |
| **Induction Mortality**                                              |                 |                 |         |
| Total                    | 13 (16.8)       | 12 (16.6)       | 0.97    |
| I1                       | 8 (10.3)        | 8 (11.1)        |         |
| I2                       | 5 (6.4)         | 4 (5.5)         |         |
| **Cause for induction mortality**                                     |                 |                 |         |
| Sepsis                   | 11 (14.2)       | 9 (12.5)        | 0.74    |
| Intracranial hemorrhage  | 1               | 1               |         |
| Pulmonary hemorrhage     | 0               | 2               |         |
| Gastrointestinal hemorrhage| 1         | 0               |         |
| Consolidation mortality  | 0               | 1               | 0.96    |
| **Cause of consolidation mortality**                                  |                 |                 |         |
| Febrile neutropenia      | 0               | 1               | 0.9     |
| **Duration of I1 (days)***                                           |                 |                 |         |
| Median                   | 26              | 26              | 0.46    |
| Mean, SD                 | 23.01, 10.33    | 21.72, 10.86    |         |
| **Duration of I2 (days)***                                           |                 |                 |         |
| Median                   | 22              | 22              | 0.93    |
| Mean, SD                 | 20.33, 8.73     | 20.44, 6.9      |         |
| **Dose reduction**                                                  |                 |                 |         |
| Total                    | 14 (18.1)       | 5 (6.9)         | 0.03    |
| I1                       | 2               | 4               |         |
| I2                       | 1               | 0               |         |
| First consolidation      | 4               | 0               |         |
| Second consolidation     | 7               | 1               |         |
| **Positive blood culture in I1 (patients)**                          |                 |                 |         |
| Total                    | 14 (18.1)       | 8 (11.1)        | 0.22    |
consolidation. Fifty-two out of 77 (67.5%) patients in the DA arm and 51 out of 72 (70.8%) patients in the ADE arm received the second HIDAC consolidation (Fig. 1). Two patients in the DA arm (one patient developed cardiomyopathy and the other persistent pancytopenia) and three patients in the ADE arm (one patient developed appendicitis and the other two had poor performance status due to septic shock) did not receive the second induction. They were planned for three HIDAC consolidations. One patient with

| Table 3. continued | DA (n = 77) (%) | ADE (n = 72) (%) | p value |
|--------------------|----------------|-----------------|--------|
| Gram-positive/MDR  | 3/2            | 4/2             |        |
| Gram-negative/MDR  | 11/2           | 4/2             |        |
| Positive blood culture in I2 (patients) | 8 (10.3) | 5 (6.9) | 0.45 |
| Gram-positive/MDR  | 2/1            | 1/0             |        |
| Gram-negative/MDR  | 6/3            | 4/3             |        |
| Number of days of antibiotics in I1 | 16.79, 5.62 | 16.01, 6.47 | 0.78^+ |
| Number of days of antibiotics in I2 | 11.61, 5.32 | 9.57, 6.18 | 0.05^+ |
| Antibiotics use in I1^# (number of patients) | 20 | 16 | 0.95 |
| None               | 2              | 6               | 0.08 |
| First line         | 30             | 22              |        |
| Second line        | 8              | 15              |        |
| Third line         | 40             | 40              |        |
| Antibiotics use in I2^# (number of patients) | 2 | 6 | 0.85^+ |
| None               | 2              | 6               |        |
| First line         | 30             | 22              |        |
| Second line        | 8              | 15              |        |
| Third line         | 26             | 18              |        |
| I1 PRBC transfusions | 4.32, 2.94 | 4.42, 3.72 | 0.85^+ |
| Mean, SD           | 17.72, 15.20   | 16.1, 14.2      | 0.5^+ |
| I2 PRBC transfusions | 1.88, 1.67 | 2, 2           | 0.37^+ |
| Mean, SD           | 8.54, 9.18     | 6.25, 7.21      | 0.13^+ |
| Relapses (morphological) | 32 | 27 | 0.61 |
| Second-line chemotherapy at relapse | 11 (14.2) | 9 (12.5) | 0.74 |
| Allogenic HSCT      |                |                |        |
| Total               | 10 (12.9)      | 4 (5.5)         | 0.12  |
| First complete morphological remission (CR1) | 4 | 2 |        |
| Second complete morphological remission (CR2) | 6 | 2 |        |
| HSCT outcome        |                |                |        |
| Alive               | 5              | 2               | 0.28  |
| CR1 transplant      | 2              | 0               |        |
| CR2 transplant      | 3              | 2               |        |
| Treatment abandonment | 3 (3.8) | 4 (5.5) | 0.63 |

*I1 First induction, I2 Second induction, DA Daunorubicin and ara-C, ADE ara-C, Daunorubicin, and Etoposide, MDR Multi-Drug Resistant, PRBC Packed Red Blood Cells, HSCT Hematopoietic Stem Cell Transplantation, ^t-Test. ^Includes patients who had postmortem bone marrow aspiration. ^#Patients in complete remission (CR) or CR with incomplete recovery (CRI) in I1 did not undergo bone marrow after I2 unless there was a suspicion of disease relapse. CR rates in I2 include patients who achieved CR in I1. ^ First line (Cefaperazone sulbactam with teicoplanin or amikacin, cefepime), Second line, (Meropenem, imipenem), Third line (Colistin, tigecycline). ^^Includes patients with not evaluable bone marrow in first induction. 

**Reply:** The duration of I1 was from the day of the start of I1 to the start of I2. The duration of I2 was defined from the day of the start of I2 to the start of the first HIDAC. If patients did not start I2 or consolidation due to mortality or treatment abandonment, the date of death or abandonment was used to calculate the duration.
Table 4. Comparison of grade 3–5 toxicities between the two study arms.

| Toxicity               | DA (n = 77) | ADE (n = 72) | p value |
|------------------------|-------------|--------------|---------|
| Cardiac                | 5 (6.5%)    | 6 (8.3%)     | 0.66    |
| Renal                  | 2 (2.6%)    | 5 (6.9%)     | 0.21    |
| Hepatic                | 4 (5.2%)    | 5 (6.9%)     | 0.65    |
| Neurological           | 3 (3.9%)    | 0            | 0.66    |
| Mucositis/Diarrhea     | 5 (6.5%)    | 6 (8.3%)     | 0.66    |
| Pulmonary              | 1 (1.2%)    | 3 (4.1%)     | 0.27    |
| I1 Febrile neutropenia | 77 (100%)   | 72 (100%)    | 0.96    |
| I2 Febrile neutropenia | 64/66 (97%) | 55/61 (90%)  | 0.11    |

DA Daunorubicin and ARAC, ADE ARAC, Daunorubicin and Etoposide, I1 First induction, I2 Second induction.

the refractory disease in the DA arm received two cycles of HIDAC. This patient was later lost to follow-up. Three patients with refractory disease in the ADE arm after the second induction received HIDAC consolidation; two received one cycle of HIDAC consolidation, and one patient received two cycles of HIDAC followed by allogeneic HSCT. There were no deaths during consolidation in the DA arm. One patient in the ADE arm died due to febrile neutropenia and sepsis after receiving the second HIDAC cycle.

Toxicities
Grade 3–5 toxicities across all chemotherapy cycles are reported in Table 4. There were no significant differences in toxicities between the study arms. Cardiomyopathy and mucositis/diarrhea were the most common toxicities in the study arms.

Two deaths post induction were treatment-related. One patient in the DA arm developed cardiomyopathy after the first HIDAC cycle. This patient did not receive the second HIDAC cycle and died due to cardiomyopathy four months after the first HIDAC cycle. One patient in the ADE arm died due to febrile neutropenia and sepsis after receiving the second HIDAC cycle.

Relapses
Fifty-nine (39.5%) patients relapsed after achieving CR, 32/77 (41.5%) in DA and 27/72 (37.5%) in the ADE arm (p = 0.61). The mean and median time to relapse in the whole cohort was 17.55 and 11.07 months (SD: 17.19, range: 3.47–91 months). The mean and median time to relapse in the DA arm was 17.08 and 10.16 months (SD:18.58, range: 3.6-91 months). The mean and median time to relapse in the ADE arm was 18.1 and 14.13 months (SD:15.71, range: 3.47-73.6 months). There was no significant difference in the mean time to relapse between the study arms (p = 0.82). All patients relapsed in the bone marrow; there were no extramedullary relapses. Twenty-one out of 59 (35.5%) patients received salvage chemotherapy (12 in the DA arm and 9 in the ADE arm), among whom eight underwent allogeneic HSCT (6 in the DA and 2 in the ADE arm). At the last follow-up, nine patients were alive and in CR including five patients who underwent allogeneic HSCT (3 in DA and 2 in the ADE arm).

Allogeneic HSCT
Fourteen patients received allogeneic HSCT, ten in DA (four in first remission and six in second) and four (two in first remission and two in second) in the ADE arm. Seven out of 14 patients are alive post HSCT, all in CR (Table 3).

One hundred patients were eligible for allogeneic HSCT in first remission, this included 61 patients with intermediate risk, 33 with adverse risk, 5 with risk not classified, and one with favorable risk and refractory disease. However, only 6 patients underwent HSCT in the first CR. The reasons for not performing allogeneic HSCT in the first CR in 94 eligible patients are described in Supplemental Table S3.

Survival outcome
The median duration of follow-up was 50.9 months (95% CI: 40.3–63.8 months). Three patients abandoned treatment in the DA arm and four in the ADE arm. The details of treatment abandonment have been provided in Supplemental Table S4. Three patients were lost to follow-up after the planned treatment, two in the DA arm and one in the ADE arm. One patient in the DA arm in CR was lost to follow-up after 34 months and seven days of completing treatment; the second patient in the DA arm had refractory disease after two cycles of induction and was lost to follow-up after 16 months and 17 days of completing the second HIDAC. The patient in the ADE arm was in CR and was lost to follow-up after 31 months.

The 5-year EFS in the DA and ADE arm was 34.4% (95% CI: 23.6–45.6) and 34.5% (95% CI: 22.7–46.4), respectively (p = 0.66) (Fig. 2A). The 5-year OS in the DA and ADE arm was 41.4% (95% CI: 29.5–52.8) and 42.09% (95% CI: 29.7–53.9), respectively (p = 0.74) (Fig. 2B).

The median EFS and OS in the whole cohort were 16.57 (95% CI: 10.14–23) and 23.77 months (95% CI: 11.41–36.13). The median EFS in the DA arm was 11.37 months (95% CI: 1.49–21.24), and the median OS was 17.17 months (95% CI: 9.07–25.26) (p = 0.66). The median OS in the DA arm was 25.53 months (95% CI: 6.22–44.8), and in the ADE arm was 23.33 months (95% CI: 0–54.51) (p = 0.74). There was no significant difference in EFS and OS for eligible patients who underwent HSCT in the first remission versus eligible patients who did not (Supplemental Fig. S2A and B) and patients who underwent HSCT in the first or second remission versus those who did not (Supplemental Fig. S2C and D).

Univariate and multivariate analyses for factors predicting the EFS and OS in the total cohort, DA arm, and ADE arm have been provided in Supplemental Tables S5 to S12. On multivariate analysis for EFS in the ADE arm, CR after the first induction (< 0.001), age below ten years (< 0.001), and WBC count less than 50,000/cumm (p = 0.011) were associated with better EFS. On multivariate analysis for OS in the ADE arm, CR after the first induction (< 0.001), age below ten years (< 0.001), and trial site difference was associated with better OS. None of the variables predicted EFS and OS in multivariate analysis in the DA arm. For the whole cohort, inferior EFS and OS were associated with not achieving CR after the first induction (p = 0.001 and 0.002, respectively), and the trial site (p = 0.027 and 0.012, respectively), and undernutrition at diagnosis predicted inferior OS (p = 0.014).

DISCUSSION
Collaborative groups in the United Kingdom, the United States of America, and Germany have used a three-drug induction regimen in their ongoing research protocols or recently published studies (Supplemental Table S3). The primary objective of our study was to compare the EFS between a 2-drug DA induction regimen with a 3-drug ADE induction regimen. We wanted to evaluate if adding a third drug to 2-drug induction improved survival outcomes and if it was associated with more toxicities and increased supportive care requirements. Knowing this is important in resource-constrained settings in LICs and LMICs where treatment of pediatric AML is challenging due to the high prevalence of gram-negative multi-drug resistant (MDR) bacterial infections, financial constraints, and restricted supportive care.

The spectrum of bacterial infections in LICs and LMICs is different from HICs [18]. Gram-negative and MDR infections are
more common among patients with cancer in LICs and LMICs [18, 19]. In contrast, gram-positive infections are more common in HICs [20]. A high proportion of patients with acute leukemia in LMICs are colonized with gram-negative MDR bacteria in stool at admission, indicating that these were community-acquired [21, 22]. MDR gram-negative bacterial infections are associated with a high incidence of mortality [23, 24]. Twenty out of 25 (80%) induction mortality in our study was due to sepsis (Table 3). Twenty-five out of 35 (71%) positive blood cultures during the induction period in the study were due to gram-negative bacteria, among whom 10 (40%) had MDR bacteria (Table 3). Six out of 10 (60%) patients with MDR gram-negative bacteremia died. Addressing gram-negative infections and MDR bacteria is vital to improving survival in pediatric AML in LICs and LMICs.

Our study did not find a significant difference in EFS between the DA and ADE arms (5-year EFS: 34.4% and 34.5%, respectively, \( p = 0.66 \)). There were no significant differences between the ADE and DA arms regarding toxicities and supportive care requirements. However, since we did not achieve our planned accrual, our study is not adequately powered to confirm our findings.

Options for treatment after relapse in pediatric AML are limited in developing countries due to the high cost of salvage chemotherapy, allogeneic HSCT, and limited donor availability. Though HSCT in the first CR was advised for intermediate and high-risk patients, only 6% underwent allogeneic HSCT. The participating centers performed only matched sibling donor HSCT until 2018, limiting the number of patients receiving HSCT. Other factors related to meager rates of HSCT were the high cost of salvage chemotherapy and HSCT, protracted treatment course and follow-up, prohibiting long-term commitment from the family/caregiver, family’s apprehension of the risk to the donor, and overall transplant outcomes, besides other socioeconomic issues. Only 21 out of 59 (35.5%) patients who relapsed in the study received chemotherapy at relapse. The high cost of salvage chemotherapy at relapse and HSCT was the most common reason why most patients at relapse did not undergo HSCT in our study. Access to HSCT is limited to most patients with AML in LMICs and is not unique to our study. The participating centers in the trial are routinely performing haploidentical HSCT and matched unrelated donor transplants since 2018; this has increased the number of patients eligible for HSCT [25]. The inclusion of HSCT under state insurance has also reduced the cost, improving access to the procedure.

The induction mortality, the CR rates, and the 5-year EFS and OS reported from our study are inferior to the results from trials from HICs (Supplemental Table S13). Ninety percent of children with cancers are treated in LICs and LMICs, and our results reflect the reality for most children with AML [26]. A recent systematic review of literature on outcomes of pediatric AML in LMICs included 27 studies, 26 retrospective, and one prospective observational study [7]. The 5-year EFS varied from 24% to 63%, and the 5-year OS from 10% to 72% [7]. The authors concluded that outcomes of pediatric AML in LMICs are substantially inferior compared to HICs [7]. There is heterogeneity in the outcomes reported from LMICs. The inferior outcomes in LMICs are due to high abandonment rates, early deaths, treatment-related mortality, and limited treatment options after relapse [7].

Thirty-nine percent of the study patients were undernourished at diagnosis, and 1.3% were obese. On univariate analysis, undernutrition at diagnosis was associated with inferior EFS and OS in the whole cohort and the ADE arm but not in the DA arm (Supplemental Tables S5 and S6). On multivariate analysis, undernutrition at diagnosis was one of the factors associated with inferior OS (Supplemental Table S8). In contrast, in the NOPHO-AML 2004 study, only 5% of patients were undernourished [27]. In the NOPHO-AML 2004 study, there was a trend toward better overall survival in obese children (23% of patients) above ten years [27]. In the Children’s Cancer Group 2961 study, 10.9% were underweight, and 14.8% were overweight. Survival was inferior, and treatment-related mortalities were higher in underweight and overweight patients than in normal-weight patients [28]. Aggressive nutritional support and tailoring cytotoxic treatment to the patient’s nutritional status might improve the overall outcomes in pediatric AML in LICs and LMICs.

Sixty-five patients screened for enrollment in the study were not eligible as they were not fit for intensive chemotherapy. This
subgroup equals 44% of patients enrolled in the trial. Many patients in LICs and LMICs present late and in moribund condition. Most are malnourished and have ongoing infections or organ dysfunction requiring intensive care. Hence, they cannot be given intensive chemotherapy due to the high risk of mortality from chemotherapy [29].

Patients who achieved CR after the first induction in our study had significantly better survival than those who did not. This was observed in the whole cohort and those who received the ADE regimen. Whether a second induction is necessary after achieving CR with the first induction needs to be explored. Omitting second induction and replacing it with HIDAC consolidation in pediatric AML can reduce the risk of cardiac toxicity and second malignancies due to a reduction in anthracycline and etoposide cumulative dose. Patients who do not achieve CR after the first induction should be considered for intensive chemotherapy followed by allogenetic HSCT, as our study shows that they have inferior outcomes even if they achieve CR after the second course of induction, especially in the ADE arm.

Based on our sub-group analysis, an etoposide-based three-drug induction might be more effective in patients less than ten years of age, with favorable cytogenetics, those with an extramedullary disease, and those who are not malnourished (Supplemental Tables S5, S6, S9 and S10).

We used etoposide as the third drug in our intervention arm as the ADE regimen is the most common three-drug induction used in pediatric AML trials (Supplemental Table 13) and routine clinical practice. Studies in adult AML have shown increased CR rates and survival with the addition of fludarabine or cladribine to induction chemotherapy regimens [10, 30, 31]. The AML-08 trial compared clofarabine and ara-C induction with ADE in pediatric AML [32]. The study showed increased MRD negative rates with clofarabine-based induction, however, this did not translate to improvements in EFS or OS [32]. The addition of fludarabine or cladribine or clofarabine and omitting etoposide in pediatric AML induction needs further evaluation.

The limitations of our study include the inability to achieve the desired sample size, the absence of MRD-based risk-stratification, and limited access to HSCT. The dose and schedule of daunorubicin and ara-C were different between the DA and ADE arms. We used a dose and schedule of DA and ADE regimens used in routine clinical practice and reported in the literature. However, our study is the first RCT on pediatric AML from LICs and LMICs. The study also challenges the dogma of three-drug induction chemotherapy in pediatric AML.

To conclude, no statistically significant difference in EFS, OS, CR, or toxicity between ADE and DA regimens in pediatric patients with AML was observed in our study. Future RCTs are needed to find the optimal number of induction chemotherapy drugs and cycles in pediatric AML.

DATA AVAILABILITY
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

REFERENCES
1. Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Curr Opin Pediatr. 2020;32:57–66.
2. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2015;33:2949–62.
3. Reinhardt D, Antoniou E, Waack K. Pediatric Acute Myeloid Leukemia—Past, Present, and Future. J Clin Med. 2022;11:504.
4. Alexander TB, Wang L, Inaba H, Tripplett BM, Pounds S, Ribeiro RC, et al. Decreased relapsed rate and treatment-related mortality contributed to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials: Improving EFS for Pediatric AML. Cancer. 2017;123:3791–8.
5. Arora RS, Arora B. Acute leukemia in children: A review of the current Indian data. South Asian J Cancer. 2021;10:155–60.
6. Kulkarni KP, Marwaha RK. Childhood Acute Myeloid Leukemia: An Indian Perspective. Pediatr Hematol Oncol. 2011;28:257–68.
7. Van Weeldeeren RE, Klein K, Natwedjja MD, De Vries R, Kaspers GJ. Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. Expert Rev Anticancer Ther. 2021;21:765–80.
8. Ganguly S, Kinsey S, Bakhshi S. Childhood cancer in India. Cancer Epidemiol. 2021;71:101679.
9. Gupta VG, Arora B, Radhakrishnan V, Banavali S, Bakhshi S. Treatment rates of paediatric acute myeloid leukemia: a view from three tertiary centres in India. Br J Haematol. 2016;175:346–7.
10. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. J Clin Oncol. 2013;31:3360–8.
11. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wareley K, Gray RG, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89:2311–8.
12. Creutzig U, Ritter J, Zimmermann M, Herrmann J, Gadner H, Sawatzki DB, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia. 2001;15:348–54.
13. O’Brien TA, Russell SJ, Vowels MR, Oswald CM, Tiedemann K, Shaw PJ, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children’s Cancer Study Group. Blood. 2002;100:2708–16.
14. Döhner H, Esteri G, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
15. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed 15 Apr 2022).
16. Growth reference 5-19 years - Application tools. https://www.who.int/tools/growth-reference-data-for-5to19-years/application-tools (accessed 10 Apr 2022).
17. Radhakrishnan V, Thampy MG, Ganesan P, Rajendranath R, Ganesan TS, Rajalekshmy KR, et al. Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India. Indian J Hematol Blood Transfus. 2016;32:257–61.
18. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Lond Engl. 2022;399:629–55.
19. Radhakrishnan V, Vijayakumar V, Ganesan P, Rajendranath R, Triviadi G, Tenali S. Bloodstream infections in pediatric patients at Cancer Institute, Chennai. Indian J Cancer. 2014;51:1418–9.
20. Grattoni G, Mikulska M. Bloodstream infections in neutrophenic cancer patients: A practical update. Virulence. 2016;7:280–97.
21. Shankar K, Radhakrishnan V, Vijayakumar V, Ramamourthy J, Ganesan P, Dhanushkodi M, et al. Prevalence of multi-drug resistant organisms in stool of paediatric patients with acute leukemia and correlation with blood culture positivity: A single institution experience. Pediatr Blood Cancer. 2018;65:26740.
22. Thacker N, Pereira N, Banavali SD, Narula G, Vora T, Chinnavasamy G, et al. Alarming prevalence of community-acquired multidrug-resistant organisms colonization in children with cancer and implications for therapy: A prospective study. Indian J Cancer. 2014;51:442–6.
23. Murali NA, Ganesan P, Vijayakumar V, Kannan K, Radhakrishnan V, Ganesan TS, et al. Increasing incidence of multidrug-resistant Gram-negative septicaemia during induction therapy of acute myeloid leukaemia. J Hosp Infect. 2016;93:314–5.
24. Manyahi J, Kibwana U, Mgilma E, Majigo M. Multi-drug resistant bacteria predict mortality in bloodstream infection in a tertiary setting in Tanzania. PLoS One. 2020;15:e0220424.
25. Batra A, Perumal Kalaiyassiy J, Kannan K, Mehra N, Ganesan P, Karunakaran P, et al. Haplodiploident Hematopoietic Stem Cell Transplantation in Leukemia’s Experience from a Cancer Center in India. Indian J Hematol Blood Transfus. 2021;37:463–71.
26. Lam CG, Howard SC, Bouffet E, Pritchard-Jones K. Science and health for all children with cancer. Science. 2019;363:1182–6.
27. Laermann DJA, Abrahamsson J, Ha S-Y, Jonsson OG, Koskenvuo M, Lausen B, et al. Effects of age and body weight on growth and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica. 2016;101:1359–67.
28. Lange BJ. Mortality in Overweight and Underweight Children With Acute Myeloid Leukemia. JAMA. 2005;293:203.
29. Bansal D, Davidson A, Supriyadi E, Njungena F, Ribeiro RC, Kaspers GJL. SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings. Pediatr Blood Cancer. 2019;72:e28087.
ACKNOWLEDGEMENTS
We thank Dr. Nadeem Ahmed, Dr. Jerin Ovett, and Ms. Vanitha for helping resolve data queries. We thank our data managers, Ms. Rohini and Ms. Mubina, for helping with data collection and ethics committee audits.

AUTHOR CONTRIBUTIONS
VR, TSG, and CT conceived and designed the study. VR, SB, AB, CT, PKS, HK, SC, RB, and BD were involved with data collection. VR and SR conducted the data analysis. VR, TSG, SB, SK, AB, CT, PKS, HK, and BD managed the patients in the trial. VR wrote the original draft, which was reviewed and approved by all co-authors. All authors had access to the raw data. VR, SB, and SK directly accessed and verified the underlying data reported in the manuscript.

FUNDING
No external source of funding was used.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-022-00726-1.

Correspondence and requests for materials should be addressed to Venkatraman Radhakrishnan.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022